Op Ed Beware the Perils of Over-Regulation for ICOs

Op Ed Beware the Perils of Over-Regulation for ICOs Last week, the U.S. Food and Drug Administration FDA approved the gene drug Kymriah for certain types of cancer. However, Kymriah costs $475,000 for one single treatment, Bloomberg reports, which is well beyond being affordable for average patients.In the U.S., the FDA approval process itself adds billions of dollars to drug development costs, which pharmaceutical companies must then recover, and also adds years to the drug availability timeline. The impression that suffering U.S. patients ar Bitcoins News Zeler